03:03 , Jan 26, 2019 |  BioCentury  |  Product Development

Target wide, test narrow in lupus

While last year’s spate of clinical misses in lupus leave the field still in search of optimal targets, the 2019 outlook isn’t all doom. Companies with shots on goal are using sharper endpoints and aiming...
05:09 , Jan 5, 2019 |  BioCentury  |  Product Development

Bristol-Myers’ next phoenix act?

Bristol-Myers Squibb Co. will now be in the driver’s seat to monetize the assets gained from the myriad deals Celgene Corp. has forged. The pharma will need to mimic its history of using well-timed acquisitions...
19:05 , Jan 4, 2019 |  BC Week In Review  |  Company News

New Year splash as BMS to acquire Celgene in $74B deal

The biggest biotech takeout in a decade brings a tumultuous 15 months for Celgene Corp. (NASDAQ:CELG) to an end as Bristol-Myers Squibb Co. (NYSE:BMY) proposed on Jan. 3 to acquire the bellwether for $74 billion....
14:08 , Jan 3, 2019 |  BC Extra  |  Company News

New Year splash as BMS to acquire Celgene in $74B deal

The biggest biotech takeout in a decade brings a tumultuous 15 months for Celgene Corp. (NASDAQ:CELG) to an end as Bristol-Myers Squibb Co. (NYSE:BMY) proposed Thursday to acquire the bellwether for $74 billion. BMS cited...
02:50 , Nov 2, 2018 |  BC Innovations  |  Targets & Mechanisms

Rethinking definitions of autoimmune disease

The autoimmune field is dialing up its search for better biomarkers as it seeks to make the next step change from the targeted therapies that overtook blanket immunosuppressants. The question is whether autoimmunity might follow...
22:41 , Sep 13, 2018 |  BC Week In Review  |  Clinical News

Higher doses of BMS's psoriasis candidate hit Phase II efficacy mark

Bristol-Myers Squibb Co. (NYSE:BMY) said four of five doses of BMS-986165 met the primary endpoint in the Phase II IM011-011 trial to treat moderate to severe plaque psoriasis. The compound, an oral tyrosine kinase 2...
14:08 , Sep 12, 2018 |  BC Extra  |  Clinical News

Higher doses of BMS's psoriasis candidate hit Phase II efficacy mark

Bristol-Myers Squibb Co. (NYSE:BMY) said four of five doses of BMS-986165 met the primary endpoint in the Phase II IM011-011 trial to treat moderate to severe plaque psoriasis. The compound, an oral tyrosine kinase 2...
22:08 , Oct 5, 2017 |  BC Innovations  |  Product R&D

Nimble move

Celgene Corp. ’s deal with Nimbus Therapeutics LLC is another vote of confidence that Nimbus’ computational drug design technology can solve druggability problems that trip up standard medicinal chemistry. The partnership gives Celgene access to...